Hayes, D
Clinical trial results Sarcoidosis-associated small fiber neuropathy: In a blinded, placebo-controlled trial, 28 days of daily subcutaneous ARA-290 administration in patients with documented small nerve fiber loss produced significant improvements
Peptide therapy might be worth considering if you are experiencing chronic fatigue or brain fog that affects your quality of life, inflammatory conditions that are not responding well to conventional care, autoimmune flares that keep returning, digestive issues or slow healing, early signs of cognitive decline, or the sense that you are not aging as well as you would like
Usually, confirmation means running an observational study to test the potential cause against a control group
Cannot redeclare control with same name "grid_6_lightbox_overlay_color"
209 , 449.e1449.e7 (2013)